- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Jubilant Pharmova's Q1 FY27 revenue grew 17% to Rs 2,229 Cr. EBITDA fell 11% to Rs 268 Cr due to SPECT product issues & Montreal costs. SPECT production resumes; H2 FY27 recovery expected. CDMO Line 3 ramps up, Line 4 installed, US$60M+ PET expansion underway.